Literature DB >> 21577308

Mesalamine induced symptom exacerbation of ulcerative colitis: Case report and brief discussion.

Maneesh Kumar Gupta1, Scott Pollack, John J Hutchings.   

Abstract

This paper describes a rare case in which the oral administration of mesalamine resulted in the exacerbation of ulcerative colitis (UC) in a patient who was previously responsive to mesalamine and whose colitis had been in remission for eight years. Mesalamine and other 5-aminosalicylic acid compounds are the mainstay of treatment for UC; however up to 8% of patients are unable to take the medications due to intolerance or hypersensitivity reactions. Common drug reactions are fever, nausea, diarrhea and abdominal pain; however, exacerbation of UC has rarely been reported. This study highlights the importance of ruling out mesalamine as the causative agent in cases of UC exacerbations.

Entities:  

Keywords:  Adverse drug reaction; Exacerbation; Inflammation; Mesalamine; Ulcerative colitis

Year:  2010        PMID: 21577308      PMCID: PMC3091157          DOI: 10.4292/wjgpt.v1.i6.132

Source DB:  PubMed          Journal:  World J Gastrointest Pharmacol Ther        ISSN: 2150-5349


  7 in total

1.  Mesalamine intolerance mimics symptoms of active inflammatory bowel disease.

Authors:  Elizaveta Iofel; Anupama Chawla; Fredric Daum; James Markowitz
Journal:  J Pediatr Gastroenterol Nutr       Date:  2002-01       Impact factor: 2.839

2.  Mesalamine enema-induced exacerbation of ulcerative colitis.

Authors:  A Bousseaden; F Z Ajana; W Essamri; I Benelbarhdadi; R Afifi; M Benazzouz; A Essaid
Journal:  Int J Colorectal Dis       Date:  2009-05-15       Impact factor: 2.571

3.  Diarrhea associated with mesalamine in a patient with chronic nongranulomatous enterocolitis.

Authors:  K D Fine; H E Sarles; B Cryer
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

4.  Exacerbation of chronic ulcerative colitis with mesalamine.

Authors:  J B Sturgeon; P Bhatia; D Hermens; P B Miner
Journal:  Gastroenterology       Date:  1995-06       Impact factor: 22.682

5.  Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine.

Authors:  M H Giaffer; C J O'Brien; C D Holdsworth
Journal:  Aliment Pharmacol Ther       Date:  1992-02       Impact factor: 8.171

6.  Mesalazine induced exacerbation of ulcerative colitis.

Authors:  K C Kapur; G T Williams; M C Allison
Journal:  Gut       Date:  1995-12       Impact factor: 23.059

7.  An experiment to determine the active therapeutic moiety of sulphasalazine.

Authors:  A K Azad Khan; J Piris; S C Truelove
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

  7 in total
  12 in total

1.  Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts.

Authors:  Ryan C Ungaro; Berkeley N Limketkai; Jean-Frederic Colombel; Tine Jess; Camilla Bjørn Jensen; Kristine Højgaard Allin; Manasi Agrawal; Thomas Ullman
Journal:  Gut       Date:  2018-11-12       Impact factor: 23.059

Review 2.  Mesalamine in the treatment and maintenance of remission of ulcerative colitis.

Authors:  Maggie Ham; Alan C Moss
Journal:  Expert Rev Clin Pharmacol       Date:  2012-03       Impact factor: 5.045

Review 3.  Strategies for the care of adults hospitalized for active ulcerative colitis.

Authors:  Suresh Pola; Derek Patel; Sonia Ramamoorthy; Elisabeth McLemore; Marianne Fahmy; Jesus Rivera-Nieves; John T Chang; Elisabeth Evans; Michael Docherty; Mark Talamini; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2012-07-24       Impact factor: 11.382

4.  Isolated fever induced by mesalamine treatment.

Authors:  Rita Slim; Joseph Amara; Roy Nasnas; Khalil Honein; Joseph Bou Jaoude; Cesar Yaghi; Fady Daniel; Raymond Sayegh
Journal:  World J Gastroenterol       Date:  2013-02-21       Impact factor: 5.742

5.  Mesalamine treatment mimicking relapse in a child with ulcerative colitis.

Authors:  Iva Hojsak; Ana M Pavić; Sanja Kolaček
Journal:  World J Pediatr       Date:  2014-06-28       Impact factor: 2.764

6.  Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis.

Authors:  Seth R Shaffer; Elbert Huang; Shivani Patel; David T Rubin
Journal:  Am J Gastroenterol       Date:  2021-01-01       Impact factor: 12.045

7.  A Case of Right-Sided Ulcerative Colitis with Mesalamine-Induced Hypersensitivity Reactions.

Authors:  Haruka Hirono; Kazuhiko Watanabe; Katsuhiko Hasegawa; Terasu Honma; Yoichi Ajioka; Shogo Ohkoshi
Journal:  Am J Case Rep       Date:  2018-05-31

8.  Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine.

Authors:  Kavinderjit Nanda; Alan C Moss
Journal:  Clin Pharmacol       Date:  2012-07-25

9.  Mesalamine Intolerance in Three Children with Crohn's Disease.

Authors:  Ceyda Tuna Kirsaclioglu; Zarife Kuloglu; Gonca Ustundag; Aydan Kansu; Erdal İnce; Arzu Ensari; Nurten Girgin
Journal:  Med Princ Pract       Date:  2015-12-02       Impact factor: 1.927

10.  5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis.

Authors:  Jun Miyoshi; Katsuyoshi Matsuoka; Atsushi Yoshida; Makoto Naganuma; Tadakazu Hisamatsu; Tomoharu Yajima; Nagamu Inoue; Susumu Okamoto; Yasushi Iwao; Haruhiko Ogata; Fumiaki Ueno; Toshifumi Hibi; Takanori Kanai
Journal:  Intest Res       Date:  2018-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.